Oracle Introduces Oracle Health Sciences Translational Research Center to Support Industry Transition to Personalized Medicine

To support more personalized, value-based healthcare, Oracle today announced the introduction of Oracle Health Sciences Translational Research Center (www.oracle.com/us/industries/health-sciences/hs-translational-research-497571.html) , a platform that facilitates the secondary use of healthcare data for both clinical and research organizations.

Oracle Health Sciences Translational Research Center enables pharmaceutical and biotech companies, contract research organizations, as well as academic research organizations to normalize, aggregate and analyze data from numerous internal and external sources to identify new predictive biomarkers, best practices for diagnosis and treatment and more effective and safe therapies for individuals.

A key component of the solution, Oracle Health Sciences Cohort Explorer, helps identify and aggregate patients with similar clinical attributes and puts powerful and easy-to-use analytics directly in the hands of researchers and clinicians, enabling them to be self-sufficient and timely in their analyses, while ensuring a secure foundation that delivers high levels of access control and traceability to support security and regulatory compliance requirements.

To speed time to value and reduce IT complexity and cost, the fully integrated solution is built on Oracle’s proven life sciences and enterprise healthcare analytics solutions. These include Oracle Healthcare Data Warehouse Foundation (www.oracle.com/us/industries/healthcare/058443.html) , a comprehensive and detailed healthcare data model that ensures high quality clinical data is readily accessible to researchers, and Oracle Health Sciences Clinical Development Center (www.oracle.com/us/industries/life-sciences/clinical-development-center-396109.html) , which provides detailed traceability of analysis processes, as well as comprehensive audit capabilities to facilitate regulatory compliance.

The initial release focuses on enabling the aggregation, normalization and analysis of clinical information, such as electronic health record data. It will help health sciences organizations gain insights into how specific patient populations respond to treatments with:

To ensure that the new platform meets the needs of health sciences organizations, Oracle worked closely with numerous development partners, including Merck (www.merck.com/index.html) , Roche (www.roche.com/index.htm) , Erasmus University Medical Center (www.erasmusmc.nl/?lang=en) , Inova Health System (www.inova.org/) , Moffitt Cancer Center (www.insidemoffitt.com/home.htm) , and Oregon Health & Science University (OHSU) Knight Cancer Institute (www.ohsu.edu/xd) .

The solution has been benchmarked on millions of patient records – demonstrating scalability for large-scale applications.

“Oracle Health Sciences Translational Research Center, developed in cooperation with leading healthcare organizations, academic research centers, and biopharmaceutical companies, is a productized, ready-to-deploy system to help enable effective personalized healthcare,” said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences. “It offers an integrated solution, built on a proven, scalable and secure platform, that enables all key stakeholders – including researchers, physicians, other clinicians and biostatisticians – to optimize each of their unique roles in the translational research continuum.”

“Oracle Health Sciences Translational Research Center will support health sciences organizations, like the Knight Cancer Institute, as we collectively work to ensure that the patient remains at the center of research and care,” said Brian Druker, M.D., director of the OHSU Knight Cancer Institute. “The ability to aggregate data, normalize it, and most importantly, effectively analyze it to yield previously unavailable insight is essential to unlocking the potential of personalized medicine.”

“Scientific discovery in healthcare continues at an unprecedented pace, and we find ourselves on the cusp of enabling full-scale translational medicine.  At Moffitt we created the foundation for this through our Total Cancer Care™ program which combines one of the largest cancer biorepositories with the collection of longitudinal clinical data. The key is mining this data for insight, putting the power to do so in the hands of the researchers who are closest to the work – and doing this in a cost-effective manner,” said Mark Hulse (www.moffitt.org/site.aspx?spid=55CD959D1BCA4CA0AE40990BA3181D1C) , R.N., vice president of Information Services and chief information officer of Moffitt. “Oracle has been a key partner with us in this effort and we believe that Oracle Health Sciences Translational Research Center will further advance the ability to deliver on these requirements.”